JP2023523016A5 - - Google Patents
Info
- Publication number
- JP2023523016A5 JP2023523016A5 JP2022564548A JP2022564548A JP2023523016A5 JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5 JP 2022564548 A JP2022564548 A JP 2022564548A JP 2022564548 A JP2022564548 A JP 2022564548A JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014550P | 2020-04-23 | 2020-04-23 | |
| US63/014,550 | 2020-04-23 | ||
| PCT/US2021/028775 WO2021216956A1 (en) | 2020-04-23 | 2021-04-23 | Compositions and methods for treating cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023523016A JP2023523016A (ja) | 2023-06-01 |
| JP2023523016A5 true JP2023523016A5 (https=) | 2024-04-26 |
| JPWO2021216956A5 JPWO2021216956A5 (https=) | 2024-04-26 |
| JP7817948B2 JP7817948B2 (ja) | 2026-02-19 |
Family
ID=78270118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564548A Active JP7817948B2 (ja) | 2020-04-23 | 2021-04-23 | がんを処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230140868A1 (https=) |
| EP (1) | EP4110822A4 (https=) |
| JP (1) | JP7817948B2 (https=) |
| KR (1) | KR20230019424A (https=) |
| CN (1) | CN115485301A (https=) |
| AU (1) | AU2021261003A1 (https=) |
| BR (1) | BR112022019939A2 (https=) |
| CA (1) | CA3172092A1 (https=) |
| IL (1) | IL296576A (https=) |
| MX (1) | MX2022013207A (https=) |
| PH (1) | PH12022553129A1 (https=) |
| WO (1) | WO2021216956A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102423686B1 (ko) * | 2019-01-10 | 2022-07-21 | 에스지메디칼 주식회사 | 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물 |
| WO2020145669A1 (ko) | 2019-01-10 | 2020-07-16 | 에스지메디칼 주식회사 | 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물 |
| WO2023056326A1 (en) * | 2021-09-30 | 2023-04-06 | Alpha Beta Holdings, Llc | Compositions and methods for treating cancer |
| CN118542937A (zh) * | 2023-02-24 | 2024-08-27 | 恒翼生物医药(上海)股份有限公司 | 抗αvβ3抗体和抗PD-1抗体的联合药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| JP2002508656A (ja) | 1997-03-12 | 2002-03-19 | スミスクライン・ビーチャム・コーポレイション | 抗−アルファベータ３ヒト化モノクローナル抗体 |
| US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| WO2002055106A2 (en) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| BR112013026828A2 (pt) * | 2011-04-21 | 2016-11-29 | Bristol Myers Squibb Co | polipeptídeos de anticorpo que antagonizam cd40 |
| CA2881981A1 (en) * | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| BR112015023752B1 (pt) * | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
| WO2015134988A1 (en) * | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| EP4353318A3 (en) * | 2017-03-31 | 2024-07-17 | The Regents of the University of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
| WO2021026024A1 (en) * | 2019-08-02 | 2021-02-11 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers |
-
2021
- 2021-04-23 MX MX2022013207A patent/MX2022013207A/es unknown
- 2021-04-23 CA CA3172092A patent/CA3172092A1/en active Pending
- 2021-04-23 CN CN202180031794.6A patent/CN115485301A/zh active Pending
- 2021-04-23 US US17/995,800 patent/US20230140868A1/en active Pending
- 2021-04-23 IL IL296576A patent/IL296576A/en unknown
- 2021-04-23 WO PCT/US2021/028775 patent/WO2021216956A1/en not_active Ceased
- 2021-04-23 KR KR1020227040872A patent/KR20230019424A/ko active Pending
- 2021-04-23 BR BR112022019939A patent/BR112022019939A2/pt unknown
- 2021-04-23 AU AU2021261003A patent/AU2021261003A1/en active Pending
- 2021-04-23 JP JP2022564548A patent/JP7817948B2/ja active Active
- 2021-04-23 EP EP21792975.1A patent/EP4110822A4/en active Pending
- 2021-04-23 PH PH1/2022/553129A patent/PH12022553129A1/en unknown